Review of NICE's recommendations, 1999-2005.
作者信息
Raftery James
机构信息
Wessex Institute of Health Research and Development, University of Southampton, Southampton SO16 7PX.
出版信息
BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.
Abstract
摘要
相似文献
1
Review of NICE's recommendations, 1999-2005.
BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.
2
Prognosis without treatment as a modifier in health economic assessments.
BMJ. 2005 Jun 11;330(7504):1382-4. doi: 10.1136/bmj.330.7504.1382.
3
Crossing the line: NICE's value for money threshold.
BMJ. 2016 Mar 9;352:i1336. doi: 10.1136/bmj.i1336.
4
The "real-life" death panel, reformed.
Hastings Cent Rep. 2011 Jan-Feb;41(1):1 p following 52.
5
How NICE may be outflanked.
BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.
6
Should NICE's threshold range for cost per QALY be raised? No.
BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.
7
Should NICE's threshold range for cost per QALY be raised? Yes.
BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.
8
Patients' views of explicit rationing: what are the implications for health service decision-making?
J Health Serv Res Policy. 2003 Jul;8(3):183-6. doi: 10.1258/135581903322029557.
9
Rational disinvestment.
QJM. 2010 Oct;103(10):801-7. doi: 10.1093/qjmed/hcq086. Epub 2010 Jun 8.
10
Searching for cost effectiveness thresholds in the NHS.
Health Policy. 2009 Aug;91(3):239-45. doi: 10.1016/j.healthpol.2008.12.010. Epub 2009 Jan 24.
引用本文的文献
1
A systematic review of whole disease models for informing healthcare resource allocation decisions.
PLoS One. 2023 Sep 14;18(9):e0291366. doi: 10.1371/journal.pone.0291366. eCollection 2023.
2
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.
Risk Manag Healthc Policy. 2020 Jan 22;13:43-53. doi: 10.2147/RMHP.S211321. eCollection 2020.
3
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Eur J Health Econ. 2018 Jan;19(1):123-152. doi: 10.1007/s10198-017-0871-0. Epub 2017 Mar 16.
4
Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.
J Manag Care Spec Pharm. 2017 Feb;23(2):247-254. doi: 10.18553/jmcp.2017.23.2.247.
5
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Medicine (Baltimore). 2016 May;95(18):e3531. doi: 10.1097/MD.0000000000003531.
6
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.
BMC Ophthalmol. 2014 Apr 14;14:49. doi: 10.1186/1471-2415-14-49.
7
Health technology assessments in England: an analysis of the NICE Medical Technologies Evaluation Programme.
Eur J Health Econ. 2014 Jun;15(5):449-52. doi: 10.1007/s10198-013-0539-3. Epub 2013 Nov 10.
8
Health economics and health technology assessment in Central and Eastern Europe: a dose of reality.
Eur J Health Econ. 2012 Oct;13(5):525-31. doi: 10.1007/s10198-012-0411-x.
9
NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.
BMJ Open. 2012 Jan 30;2(1):e000671. doi: 10.1136/bmjopen-2011-000671. Print 2012.
10
Valorising and creating access to innovative medicines in the European union.
Front Pharmacol. 2011 Oct 11;2:57. doi: 10.3389/fphar.2011.00057. eCollection 2011.
本文引用的文献
1
Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
BMJ. 2005 Jan 8;330(7482):65. doi: 10.1136/bmj.38285.482350.82. Epub 2004 Dec 15.
2
Drug policy down under: Australia's pharmaceutical benefits scheme.
Health Care Financ Rev. 2004 Spring;25(3):55-67.
3
Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Health Econ. 2004 May;13(5):437-52. doi: 10.1002/hec.864.
4
PHARMAC and availability of pharmaceuticals.
N Z Med J. 2002 Jun 7;115(1155):274; author reply 274-5.
5
NICE: faster access to modern treatments? Analysis of guidance on health technologies.
BMJ. 2001 Dec 1;323(7324):1300-3. doi: 10.1136/bmj.323.7324.1300.
6
Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue.
JAMA. 1991 May 1;265(17):2218-25.
Zotero 插件